S&P 500, Dow Jones and Nasdaq today June 29: The US stock market started the shortened trading week with solid gains as the Dow Jones close...

Initial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...

A newly formed bipartisan nonprofit named RAISE US is set to launch with over $500 million aimed at tackling job losses anticipated from ar...

India is set to implement a mandatory registration for printed pharmaceutical packaging manufacturers to combat counterfeit drugs. This mov...

The launch follows marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced ...

Healthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...

The Bombay High Court has cancelled Thane-based Menschlich Healthcare's trademark 'Duphachrit' in favour of Abbott Product Operations AG. T...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...

Electronics Mart India is diversifying its store presence beyond Hyderabad due to concerns about potential AI-driven job losses impacting c...

A new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...

Danish drugmaker Novo Nordisk has confirmed a security incident. Unauthorised access to internal IT systems occurred. Certain non-public da...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...